Highlights

Roth Capital Starts Coverage on AEterna Zentaris (AEZS)

 Source: ABMN Staff   |   Publish date: Thu, 20 Sep 08:04   |    >> Read article in News website

Research analysts at Roth Capital began coverage on shares of AEterna Zentaris (NASDAQ: AEZS) in a report released on Thursday. The firm set a “buy” rating on the stock.

AEterna Zentaris opened at 0.6801 on Thursday. AEterna Zentaris has a 1-year low of $0.38 and a 1-year high of $2.17. The company’s market cap is $76.4 million.

A number of other firms have also recently commented on AEZS. Analysts at Oppenheimer reiterated a “perform” rating on shares of AEterna Zentaris in a research note to investors on Thursday, August 16th. Analysts at RBC Capital cut their price target on shares of AEterna Zentaris from $0.70 to $0.55 in a research note to investors on Thursday, August 16th. They now have a “sector perform” rating on the stock.

Aeterna Zentaris Inc. (Aeterna Zentaris) is a drug development company specialized in oncology and endocrine therapy.

Share this

  Be the first to like this.
 


 

2704  4604  531  329 

ActiveGainersLosers
Top 10 Active Counters
 NameLastChange 
 SPY 199.45-2.54 
 EEM 39.02-1.10 
 BAC 15.15-0.28 
 PBR 6.01-0.39 
 AAPL 117.16-1.74 
 MSFT 40.40-1.61 
 VXX 36.87+3.37 
 TVIX 3.54+0.55 
 T 32.92-0.04 
 GE 23.89-0.19 
Partners & Brokers